ACINETOBACTER: MICROBIOLOGICAL, PATHOGENETIC AND RESISTANT PROPERTIES

Cover Page

Abstract


Species of the genus Acinetobacter represent opportunistic bacteria with a growing clinical significance. In this literature review, we focus on the current role of Acinetobacter in infectious pathology and describe physiology, taxonomy, ecology, pathogenicity, and antibiotic resistance of these bacteria. Molecular pathogenesis and regulation of virulence factors in Acinetobacter spp. are described in detail. The majority of acinetobacterial infections are associated with A. baumannii and occur predominantly in an immunocompromised host. Usually, acinetobacterial infections are characterized by local purulent inflammation; in severe cases, meningitis and sepsis may develop. Antibiotic resistance of Acinetobacter is a major clinical problem; therefore we give special attention to laboratory testing of resistance as well as identification of Acinetobacter. In addition, treatment and prophylaxis of acinetobacterial infections are discussed.


I. V. Chebotar'

Scientific Centre of Children Health, Moscow, Russian Federation

Author for correspondence.
Email: nizarnn@yandex.ru

Russian Federation доктор медицинских наук, ведущий научный сотрудник лаборатории микробиологии Научного центра здоровья детей Адрес: 119991, Москва, Ломоносовский пр-т, д. 2, стр. 1, тел.: +7 (499) 134-53-87

A. V. Lazareva

Scientific Centre of Children Health, Moscow, Russian Federation

Email: annalaz71@mail.ru

Russian Federation кандидат медицинских наук, заведующая лабораторией микробиологии Научного центра здоровья детей Адрес: 119991, Москва, Ломоносовский пр-т, д. 2, стр. 1, тел.: +7 (499) 134-53-87

Ya. K. Masalov

Engelhardt Institute of Molecular Biology, Moscow, Russian Federation

Email: ykmasalov@gmail.com

Russian Federation аспирант лаборатории биологических микрочипов ФГБУН «ИМБ им. В.А. Эн- гельгардта» РАН Адрес: 119991, Москва, ул. Вавилова, д. 32, тел.: +7 (499) 135-98-46

V. M. Mikhailovich

Engelhardt Institute of Molecular Biology, Moscow, Russian Federation

Email: mvm@biochip.ru

Russian Federation доктор биологических наук, ведущий научный сотрудник лаборатории биологи- ческих микрочипов ФГБУН «ИМБ им. В.А. Энгельгардта» РАН Адрес: 119991, Москва, ул. Вавилова, д. 32, тел.: +7 (499) 135-11-77

N. A. Mayanskii

Scientific Centre of Children Health, Moscow, Russian Federation

Email: mayansky@nczd.ru

Russian Federation доктор медицинских наук, заведующий лабораторным отделом Научного центра здоровья детей Адрес: 119991, Москва, Ломоносовский пр-т, д. 2, стр. 1, тел.: +7 (499) 134-02-18

  1. Boucher H.W., Talbot G.H., Bradley J.S., Edwards J.E., Gilbert D., Rice L.B., Scheld M., Spellberg B., Bartlett J. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 2009; 48 (1): 1–12.
  2. Bergey’s Manual of Systematic Bacteriology. 2nd Edition. URL: http://www.bergeys.org/outlines.html (available: 31.07.2014).
  3. Beijerinck M.W. Pigmenten als oxydatieproducten door bacterien gevormd. Versl. Koninklijke Akad. Wetensch. Amsterdam. 1911; 19: 1092–1103.
  4. Brisou J., Prevot A.R. Studies on bacterial taxonomy. X. The revision of species under Acromobacter group. Ann. Inst. Pasteur. 1954; 86 (6): 722–728.
  5. Baumann P., Doudoroff M., Stanier R.Y. A study of the Moraxella group. II. Oxidative-negative species (genus Acinetobacter). J. Bacteriol. 1968; 95: 1520–1541.
  6. Allen D.M., Wong S.Y. Acinetobacter: a perspective. Singapore Med. J. 1990; 31 (6): 511–514.
  7. Wang X., Zhang Z., Hao Q., Wu J., Xiao J., Jing H. Complete Genome Sequence of Acinetobacte baumannii ZW85-1. Genome Announc. 2014; 2 (1): 3–13.
  8. Galbraith L., Sharples J.L., Wilkinson S.G. Structure of the O-specific polysaccharide for Acinetobacter baumannii serogroup O1. Carbohydr. Res. 1999; 319 (1–4): 204–208.
  9. Pelletier M.R., Casella L.G., Jones J.W., Adams M.D., Zuraw-ski D.V., Hazlett K.R., Doi Y., Ernst R.K. Unique structural modifications are present in the lipopolysaccharide from colistin-resistant strains of Acinetobacter baumannii. Antimicrob. Agents Chemother. 2013; 57 (10): 4831–4840.
  10. Beceiro A., Llobet E., Aranda J., Bengoechea J.A., Doumith M., Hornsey M., Dhanji H., Chart H., Bou G., Livermore D.M., Woodford N. Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB two-component regulatory system. Antimicrob. Agents Chemother. 2011; 55 (7): 3370–3379.
  11. Kenyon J.J., Hall R.M. Variation in the complex carbohydrate biosynthesis loci of Acinetobacter baumannii genomes. PLoS One. 2013; 8 (4): 62160.
  12. Bergogne-Berezin E., Friedman H., Bendinelli M. Acinetobacter: Biology and Pathogenesis. New York: Springer. 2008. 236 p.
  13. King L.B., Pangburn M.K., McDaniel L.S. Serine protease PKF of Acinetobacter baumannii results in serum resistance and suppression of biofilm formation. J. Infect. Dis. 2013; 207 (7): 1128–1134.
  14. Snellman E.A., Colwell R.R. Acinetobacter lipases: molecular biology, biochemical properties and biotechnological potential. J. Ind. Microbiol. Biotechnol. 2004; 31 (9): 391–400.
  15. Jacobs A.C., Hood I., Boyd K. L., Olson P. D., Morrison J. M., Carson S., Sayood K., Iwen P.C., Skaar E.P., Dunman P.M. Inactivation of phospholipase D diminishes Acinetobacter baumannii pathogenesis. Infect. Immun. 2010; 78: 1952–1962.
  16. Camarena L., Bruno V., Euskirchen G., Poggio S., Snyder M. Molecular mechanisms of ethanol-induced pathogenesis revealed by RNA-sequencing. PLoS Pathog. 2010; 6: 1000834.
  17. Aehle W. Enzymes in Industry. Production and Applications. Weinheim: WILEY-VCH Verlag GmbH & Co. KGaA. 2007. 517 р.
  18. Visca P., Seifert H., Towner K.J. Acinetobacter infection — an emerging threat to human health. IUBMB Life. 2011; 63 (12): 1048–1054.
  19. Seifert H., Dijkshoorn L., Gerner-Smidt P., Pelzer N., Tjernberg I., Vaneechoutte M. Distribution of Acinetobacter species on human skin: comparison of phenotypic and genotypic identification methods. J. Clin. Microbiol. 1997; 35: 2819–2825.
  20. Шагинян И.А., Чернуха М.Ю. Неферментирующие грамотрицательные бактерии в этиологии внутрибольничных инфекций: клинические, микробиологические и эпидемиологические особенности. Клиническая микробиология и антимикробная химиотерапия. 2005; 7 (3): 271–285.
  21. Jawad A., Seifert H., Snelling A.M., Heritage J., Hawkey P.M. Survival of Acinetobacter baumannii on dry surfaces: comparison of outbreak and sporadic isolates. J. Clin. Microbiol. 1998; 36 (7): 1938–1341.
  22. Bhargava N., Sharma P., Capalash N. Quorum sensing in Acinetobacter: an emerging pathogen. Crit. Rev. Microbiol. 2010; 36 (4): 349–360.
  23. Bernards A.T., Harinck H.I., Dijkshoorn L., van der Reijden T.J., van den Broek P.J. Persistent Acinetobacter baumannii? Look inside your medical equipment. Infect. Control. Hosp. Epidemiol. 2004; 25: 1002–1004.
  24. Wilks M., Wilson A., Warwick S., Price E., Kennedy D., Ely A., Millar M.R. Control of an outbreak of multidrug-resistant Acinetobacter baumannii-calcoaceticus colonization and infection in an intensive care unit (ICU) without closing the ICU or placing patients in isolation. Infect. Control. Hosp. Epidemiol. 2006; 27 (7): 654–658.
  25. Weernink A., Severin W.P., Tjernberg I., Dijkshoorn L. Pillows, an unexpected source of Acinetobacter. J. Hosp. Infect. 1995; 29 (3): 189–199.
  26. Russo T.A., Luke N.R., Beanan J.M., Olson R., Sauberan S.L., Mac-Donald U., Schultz L.W., Umland T.C., Campagnari A.A. The K1 capsular polysaccharide of Acinetobacter baumannii strain 307-0294 is a major virulence factor. Infect. Immun. 2010; 78 (9): 3993–4000.
  27. Богомолова Н.С., Большаков Л.В., Кузнецова С.М. Проблема лечения гнойно-воспалительных осложнений, обусловленных Acinetobacter. Анестезиология и реаниматология. 2014; 1: 26–32.
  28. Алексеева Е.И., Слободенюк А.В. Некоторые особенности эпидемического процесса внутрибольничных инфекций в детских ожоговых отделениях. Гигиена и эпидемиология. 2007; 11 (39): 93–95.
  29. Petersen K., Riddle M.S., Danko J.R., Blazes D.L., Hayden R. Trauma-related infections in battlefield casualties from Iraq. Ann. Surg. 2007; 245: 803–811.
  30. Howard A., O’Donoghue M., Feeney A., Sleator R.D. Acinetobacter baumannii: an emerging opportunistic pathogen. Virulence. 2012; 3 (3): 243–250.
  31. Nemec A., Dijkshoorn L., and van der Reijden T.J. Long-term predominance of two pan-European clones among multi-resistant Acinetobacter baumannii strains in the Czech Republic. J. Med. Microbiol. 2004; 53: 147–153.
  32. Van Dessel Н., Dijkshoorn L., van der Reijden Т., Bakker N., Paauw A., van den Broek P., Verhoef J., Brisse S. Identification of a new geographically widespread multiresistant Acinetobacter baumannii clone from European hospitals. Res. Microbiol. 2004; 155: 105–112.
  33. Zarrilli R., Pournaras S., Giannouli M., Tsakris A. Global evolution of multidrug-resistant Acinetobacter baumannii clonal lineages. Int. J. Antimicrob. Agents. 2013; 41 (1): 11–19.
  34. Diancourt L., Passet V., Nemec A., Dijkshoorn L., Brisse S. The population structure of Acinetobacter baumannii: expanding multiresistant clones from an ancestral susceptible genetic pool. PLoS ONE. 2010; 5: 10034.
  35. Eveillard M., Kempf M., Belmonte O., Pailhoriеs H., Joly-Guillou M.L. Reservoirs of Acinetobacter baumannii outside the hospital and potential involvement in emerging human community-acquired infections. Int. J. Infect. Dis. 2013; 17 (10): 802–805.
  36. Retailliau H.F., Hightower W.A., Dixon R.E., Allen J.R. Acinetobacter calcoaceticus: a nosocomial pathogen with an unusual seasonal pattern. J. of Infect. Dis. 1979; 139: 371–375.
  37. Tomaras A.P., Dorsey C.W., Edelmann R.E., Actis L.A. Attachment to and biofilm formation on abiotic surfaces by Acinetobacter baumannii: involvement of a novel chaperone-usher pili assembly system. Microbiol. 2003; 149: 3473–3484.
  38. Smani Y., McConnell M.J., Pachon J. Role of fibronectin in the adhesion of Acinetobacter baumannii to host cells. PLoS One. 2012; 7 (4): 33073.
  39. Cerqueira G.M., Peleg A.Y. Insights into Acinetobacter baumannii pathogenicity. IUBMB Life. 2011; 63 (12): 1055–1060.
  40. Mihara K., Tanabe T., Yamakawa Y., Funahashi T., Nakao H., Narimatsu S., Yamamoto S. Identification and transcriptional organization of a gene cluster involved in biosynthesis and transport of acinetobactin, a siderophore produced by Acinetobacter baumannii ATCC 19606T. Microbiol. 2004; 150: 2587–2597.
  41. Brade H., Galanos C. Biological activities of the lipopolysaccharide and lipid A from Acinetobacter calcoaceticus. J. Med. Microbiol. 1983; 16 (2): 211–214.
  42. Kwon S.O., Gho Y.S., Lee J.C., Kim S.I. Proteome analysis of outer membrane vesicles from a clinical Acinetobacter baumannii isolate. FEMS Microbiol. Lett. 2009; 297 (2): 150–156.
  43. Grotiuz G., Sirok A., Gadea P., Varela G., Schelotto F. Shiga toxin 2-producing Acinetobacter haemolyticus associated with a case of bloody diarrhea. J. Clin. Microbiol. 2006; 44: 3838–3841.
  44. Choi C.H., Lee J.S., Lee Y.C., Park T.I., Lee J.C. Acinetobacter baumannii invades epithelial cells and outer membrane protein A mediates interactions with epithelial cells. BMC Microbiol. 2008; 8: 216.
  45. Qiu H., KuoLee R., Harris G., Van Rooijen N., Patel G.B., Chen W. Role of macrophages in early host resistance to respiratory Acinetobacter baumannii infection. PLoS One. 2012; 7: 40019.
  46. Russo T.A., Beanan J.M., Olson R., MacDonald U., Cox A.D., St Michael F., Vinogradov E.V., Spellberg B., Luke-Marshall N.R., Campagnari A.A. The K1 capsular polysaccharide from Acinetobacter baumannii is a potential therapeutic target via passive immunization. Infect Immun. 2013; 81 (3): 915–922.
  47. Rodriguez-Bano J., Marti S., Soto S., Fernandez-Cuenca F., Cisneros J.M., Pachon J., Pascual A., Martínez-Martínez L., McQueary C., Actis L.A., Vila J. Biofilm formation in Acinetobacter baumannii: associated features and clinical implications. Clin. Microbiol. Infect. 2008; 14 (3): 276–278.
  48. McQueary C.N., Actis L.A. Acinetobacter baumannii biofilms: variations among strains and correlations with other cell properties. J. Microbiol. 2011; 49 (2): 243–250.
  49. Choi A.H., Slamti L., Avci F.Y., Pier G.B. and Maira-Litran T. The pgaABCD locus of Acinetobacter baumannii encodes the production of poly-beta-1-6-N-acetylglucosamine, which is critical for biofilm formation. J. Bacteriol. 2009; 191: 5953–5963.
  50. Smith M.G., Gianoulis T.A., Pukatzki S., Mekalanos J.J., Ornston L.N., Gerstein M., Snyder M. New insights into Acinetobacter baumannii pathogenesis revealed by high-density pyrosequencing andtransposon mutagenesis. Genes Dev. 2007; 21 (5): 601–614.
  51. Горбич Ю.Л., Карпов И.А. Клинические особенности Acinetobacter baumannii-ассоциированных инфекций. Клиническая инфектология и паразитология. 2012; 1 (1): 34–45.
  52. Wisplinghoff H., Bischoff T., Tallent S.M., Seifert H., Wenzel R.P. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 2004; 39: 309–317.
  53. Bergogne-Berezin E., Joly-Guillou M.L., Vieu J.F. Epidemiology of nosocomial infections due to Acinetobacter calcoaceticus. J. Hosp. Infect. 1987; 10 (2): 105–113.
  54. Miller R.M., Polakavetz S.H., Hornick R.B., Cowley R.A. Analysis of infections acquired by the severely injured patient. Surg. Gynecol. Obstet. 1973; 137 (1): 7–10.
  55. Trottier V., Segura P.G., Namias N., King D., Pizano L.R. Outcomes of Acinetobacter baumannii infection in critically ill burned patients. J. Burn. Care Res. 2007; 28: 248–254.
  56. Charnot-Katsikas A., Dorafshar A.H., Aycock J.K., David M.Z., Weber S.G., Frank K.M. Two cases of necrotizing fasciitis due to Acinetobacter baumannii. J. Clin. Microbiol. 2009; 47: 258–263.
  57. Olut A.I., Erkek E. Early prosthetic valve endocarditis due to Acinetobacter baumannii: a case report and briefreview of the literature. Scand. J. Infect. Dis. 2005; 37 (11–12): 919–921.
  58. Palabiyikoglu I., Tekeli E., Cokca F., Akan O., Unal N. Nosocomial meningitis in a university hospital between 1993 and 2002. J. Hosp. Infect. 2006; 62: 94–97.
  59. Hoffmann S., Mabeck C. E., Veisgaard R. Bacteriuria caused bv Acinetobacter calcoaceticus biovars in a normal population and in general practice. J. Clin. Microbiol. 1982; 16: 443–451.
  60. Henao-Martinez A.F., González-Fontal G.R., Johnson S. A case of community-acquired Acinetobacter junii-johnsonii cellulitis. Biomedica. 2012; 32 (2): 179–181.
  61. Linde H.J., Hahn J., Holler E., Reischl U., Lehn N. Septicemia due to Acinetobacter junii. J. Clin. Microbiol. 2002; 40: 2696–2697.
  62. Rathinavelu S., Zavros Y., Merchant J.L. Acinetobacter lwoffii infection and gastritis. Microbes Infect. 2003; 5 (7): 651–657.
  63. Chen C.H., Wu S.S., Huang C.C. Two case reports of gastroendoscopy associated Acinetobacter baumannii bacteremia. World J. Gastroenterol. 2013; 19 (18): 2835–2840.
  64. Gaynes R., Edwards J.R. Overview of nosocomial infections caused by gram-negative bacilli. Clin. Infect. Dis. 2005; 41: 848– 854.
  65. Maragakis L.L., Perl T.M. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatmentoptions. Clin. Infect. Dis. 2008; 46 (8): 1254–1263.
  66. Levin A.S., Levy C.E., Manrique A.E., Medeiros E.A., Costa S.F. Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin / sulbactam. Int. J. Anti-microb. Agents. 2003; 21 (1): 58–62.
  67. Briggs S., Ellis-Pegler R., Raymond N., Thomas M., Wilkinson L. Gram-negative bacillary meningitis after cranial surgery or trauma in adults. Scand. J. Infect. Dis. 2004; 36: 165–173.
  68. Zarrilli R., Giannouli M., Tomasone F., Triassi M., Tsakris A. Carbapenem resistance in Acinetobacter baumannii: the molecular epidemic features of an emerging problem in health care facilities. J. Infect. Dev. Ctries. 2009; 3 (5): 335–341.
  69. Тапальский Д.В., Мозгова А.В., Козлова А.И. Чувствительность госпитальных изолятов Acinetobacter baumannii к антибиотикам и их комбинациям. Клиническая микробиология и антимикробная химиотерапия. 2014; 16 (2): 37.
  70. Справочник по антимикробной терапии. Под ред. Р.С. Козлова, А.В. Дехнича. Смоленск: МАКМАХ. 2010. 416 с.
  71. Peleg A.Y., Seifert H., Paterson D.L. Acinetobacter baumannii: emergence of a successful pathogen. Clin. Microbiol. Rev. 2008; 21: 538–582.
  72. Robledo I.E., Aquino E.E., Sante M.I., Santana J.L., Otero D.M., Leon C.F., Vazquez G.J. Detection of KPC in Acinetobacter spp. in Puerto Rico. Antimicrob. Agents Chemother. 2010; 54: 1354– 1357.
  73. Bonnin R.A., Nordmann P., Potron A., Lecuyer H., Zahar J.R., Poirel L. Carbapenem-hydrolyzing GES-type extended-spectrum beta-lactamase in Acinetobacter baumannii. Antimicrob. Agents Chemother. 2011; 55 (1): 349–354.
  74. Kempf M., Rolain J.M. Emergence of resistance to carbapen-ems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options. Int. J. Antimicrob. Agents. 2012; 39 (2): 105–114.
  75. Tian G.B., Adams-Haduch J.M., Taracila M., Bonomo R.A., Wang H.N., Doi Y. Extended-spectrum AmpC cephalosporinase in Acinetobacter baumannii: ADC-56 confers resistance to cefepime. Antimicrob. Agents Chemother. 2011; 55 (10): 4922 –4925.
  76. Quale J., Bratu S., Landman D., Heddurshetti R. Molecular epidemiology and mechanisms of carbapenem resistance in Acinetobacter baumannii endemic in New York City. Clin. Infect. Dis. 2003; 37 (2): 214–220.
  77. Poirel L., Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin. Microbiol. Infect. 2006; 12: 826–836.
  78. Gupta V., Garg R., Garg S., Chander J., Attri A.K. Coexistence of Extended Spectrum Beta-Lactamases, AmpC Beta-Lactamases and Metallo-Beta-Lactamases in Acinetobacter baumannii from burns patients: a report from a tertiary carecentre of India. Ann. Burns Fire Disasters. 2013; 26 (4): 189–192.
  79. Cai Y., Chai D., Wang R., Liang B., Bai N. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J. Antimicrob. Chemother. 2012; 67 (7): 1607–1615.
  80. Poirel L., Bonnin R.A., Nordmann P. Genetic basis of antibiotic resistance in pathogenic Acinetobacter species. IUBMB Life. 2011; 63 (12): 1061–1067.
  81. Vila J., Marti S., Sanchez-Cespedes J. Porins efflux pumps and multidrug resistance in Acinetobacter baumannii. J. Antimicrob. Chemother. 2007; 59: 1210–1215.
  82. Nemec A., Dolzani L., Brisse S., van den Broek P., Dijkshoorn L. Diversity of aminoglycoside-resistance genes and their association with class 1 integrons among strains of pan-European Acinetobacter baumannii clones. J. Med. Microbiol. 2004; 53 (12): 1233–1240.
  83. Coyne S., Courvalin P., Périchon B. Efflux-mediated antibiotic resistance in Acinetobacter spp. Antimicrob. Agents Chemother. 2011; 55 (3): 947–953.
  84. Jurenaite M., Markuckas A., Suziedeliene E. Identification and characterization of type II toxin-antitoxin systems in the opportunistic pathogen Acinetobacter baumannii. J. Bacteriol. 2013; 195 (14): 3165–3172.
  85. Чеботарь И.В., Маянский А.Н., Кончакова Е.Д., Лазарева А.В., Чистякова В.П. Антибиотикорезистентность биопленочных бактерий. Клиническая микробиология и антимикробная химиотерапия. 2012; 14 (1): 51–58.
  86. Sanchez C.J., Mende K., Beckius M.L., Akers K.S., Romano D.R., Wenke J.C., Murray C.K. Biofilm formation by clinical isolates and the implications in chronic infections. BMC Infect. Dis. 2013; 13: 47.
  87. Чеботарь И.В., Лазарева А.В., Крыжановская О.А. Отсутствие корреляции между антибиотикорезистентностью и способностью формировать биопленки у госпитальных штаммов Acinetobacter baumannii. Клиническая микробиология и антимикробная химиотерапия. 2014; 16 (2): 40.
  88. Stackebrandt E., Goebel B.M. Taxonomic note: a place for DNADNA reassociation and 16S rRNA sequence analysis in the present species definition in bacteriology. Int. J. Syst. Bacteriol. 1994; 44: 846–849.
  89. Turton J. F., Woodford J. N., Glover S., Yarde M. E., Kaufmann T., Pitt L. Identification of Acinetobacter baumannii by detection of the blaOXA-51-like carbapenemase gene intrinsic to this species. J. Clin. Microbiol. 2006; 44: 2974–2976.
  90. Glew R.H., Moellering R.C., Kunz L.J. Infections with Acinetobacter calcoaceticus (Herellea vaginicola): clinical and laboratory studies. Jr. Medicine (Baltimore). 1977; 56 (2): 79–97.
  91. Michalopoulos A., Falagas M.E. Treatment of Acinetobacter infections. Expert. Opin. Pharmacother. 2010; 11 (5): 779–788.

Views

Abstract - 84

PDF (Russian) - 25

Cited-By


PlumX

Dimensions



Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies